New Frontiers in the Treatment and Management of Cystic Fibrosis: Managed Care Considerations in an Evolving Treatment Paradigm

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2023 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 1, 2023 to August 1, 2024
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Vertex Pharmaceuticals

Description:
Cystic fibrosis (CF), also known as mucoviscidosis, is a genetic disorder that affects mostly the lungs but also the pancreas, liver, kidneys and intestine. While newborn screening for cystic fibrosis (CF) has led to greater recognition of disease, patients with CF continue to experience severe disease complications and high rates of health care resource utilization. Patients with CF require lifelong, daily prophylactic regimens to prevent exacerbations and improve disease symptoms to maintain lung function. However, CF treatment is shifting from symptomatic management to targeting the underlying CFTR mutations to manage disease progression and prevent recurring complications associated with CF. Managed care professionals have a significant role in informing patients with CF and caregivers about these available and emerging treatment interventions and ensuring access to therapies. Through member surveys, interviews, outcome reports and past conference evaluations, NAMCP has seen a great need for more education on the newer treatments in CF. It is critical to provide medical directors, practicing physicians, nurse case managers and other healthcare professionals on the updated treatment paradigm and management strategies in CF.

Upon completion of this activity, participants will be able to:

• Analyze the clinical and economic burden of cystic fibrosis in terms of drug utilization, mortality, adverse event management, and hospitalizations

• Express the burden of disease associated with CF, including the pathophysiology of disease and the impact of COVID-19 on CF patients

• Compare and contrast recent clinical data and the disease-modifying potential of current and investigational CFTR modulators in patients with CF

• Examine the potential role of messenger ribonucleic acid (mRNA) therapies in the management of patients with cystic fibrosis who do not respond to CFTR modulator therapy

• Identify patient and provider barriers and challenges, including cost, that impact identification and treatment of CF

• Discuss the managed care considerations on CFTR modulator therapies, including combination options, and explore where these agents fit in the cystic fibrosis management paradigm
  
   

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)^TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Vertex Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue